In psoriasis, GLP-1 RAs, particularly liraglutide, have been associated with improvements in the Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI), especially among patients with T2D
Basic and Applied Sci 4(8): 3553-3558
Weeks 9 to 12 (dose escalation to 1.2 mg) This is often the peak side effect period
Patients should monitor for severe persistent abdominal pain, persistent vomiting, signs of dehydration, bowel obstruction symptoms, or worsening Crohn's symptoms
Abbreviations AACE: American Association of Clinical Endocrinology AE: Adverse event CDS: Chinese Diabetes Society DPP-4i: Dipeptidyl peptidase-4 inhibitor ETD: Estimated treatment difference FPG: Fasting plasma glucose GLP-1: Glucagon-like peptide-1 GLP-1RA: Glucagon-like peptide-1 receptor agonist PIONEER: Peptide Innovation for Early Diabetes Treatment SAE: Serious adverse event SF-36v2: 36-item Short Form Health Survey (Acute Version) SMPG: Self-monitored plasma glucose References Sun H, Saeedi P, Karuranga S et al (2022) IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045